Jabez Biosciences

03/18/2026

03/18/2026

At Jabez Biosciences, we believe the future of oncology depends not only on discovery but also on scalability and real-world readiness. Through our 3-S Therapeutics Model, Seamless, Scalable, and Synergistic, we develop small-molecule therapies that prioritize patient accessibility, scalable manufacturing, and strong supply-chain reliability. By combining biology-driven insights with chemistry-led development, promising treatments like JBZ-001 can move efficiently from laboratory discovery to real-world patient care while complementing existing standards of care.
Stay informed on how we’re advancing scalable, patient-focused oncology research: https://www.jabezbio.com/
🤝 Investors interested in our chemistry-led development strategy can connect with us here: https://www.jabezsciences.com/
📞 For partnership or collaboration inquiries, reach our team at 844-748-9474
treatment

02/26/2026

Innovation in oncology is about more than science; it’s about people. Dr. Tamara Jovonovich, PhD, CEO of Jabez Biosciences, is leading with that belief at the core. With 20+ years in pharmaceutical research and translational science, she’s advancing JBZ-001, an oral DHODH inhibitor now in Phase 1 trials for advanced solid tumors and non-Hodgkin lymphoma. From dosing the first patient to expanding multi-site enrollment, real progress is underway. Guided by a “Seamless, Scalable, Synergistic” approach, Jabez is building therapies designed for real-world impact. Follow our journey as we work to bring meaningful, patient-centred cancer treatments forward.

👉 Follow Jabez Biosciences https://www.jabezbio.com/ for research updates

💬 Investors: curious about our approach? Share your details here for a conversation: https://www.jabezsciences.com/

👉 Talk to us ☎️ 844-748-9474

02/06/2026

In 2025, Jabez Biosciences reinforced how early clinical insights, metabolic research, and translational science continue to inform thoughtful oncology development. As our Phase 1 clinical trial of JBZ-001 moves forward, we remain focused on carefully evaluating safety, tolerability, and early signals to guide responsible development decisions.
At Jabez Biosciences, we translate key AACR insights, visual summaries, and behind-the-scenes reflections that connect conference data to real-world research decisions. Expect concise recaps that make complex science easier to follow and more meaningful for a broader audience.
Learn more: https://www.jabezbio.com/
Don’t wait, be part of the future of healing! Submit your details for a callback now https://www.jabezsciences.com/
General & Media Inquiries: 844-748-9474

01/13/2026

A significant moment is unfolding for JBZ-001. Our lead asset is now part of an NCI-backed Phase 1 study in AML. This step reflects disciplined pipeline expansion, a credible scientific rationale for DHODH inhibition, and partnerships that help de-risk early development. For patients, it means hope in a difficult disease area. For investors, it signals focused strategy and thoughtful growth potential as clinical milestones arrive.
Watch: https://youtu.be/RJPwLI41QAI
Don’t wait, be part of the future of healing! Submit your details for a callback now https://www.jabezsciences.com/

01/07/2026

What if cancer therapies were designed to fit real clinical environments from day one?
At Jabez Biosciences, the 3 S Model guides how JBZ 001 is developed to be simple to deliver, scalable beyond early success, and synergistic with existing standards of care.
For investors, this approach supports broader adoption, disciplined ex*****on, and a clearer path toward durable value as enrollment progresses and insights deepen.

Watch: https://youtu.be/RJPwLI41QAI
Don’t wait, be part of the future of healing! Submit your details for a callback now https://www.jabezsciences.com/

12/11/2025

Every milestone in cancer research carries a human story, and opening our second Phase-1 site is no different. For patients running out of options, expanded access means a chance to be seen, supported, and included. It also deepens our early understanding of JBZ-001, our oral DHODH inhibitor designed for simplicity, scalability, and real compatibility with today’s treatments. As enrollment grows, so does our commitment to a development path that honors both the science and the people behind it.
Watch: https://youtu.be/RJPwLI41QAI
Don’t wait, be part of the future of healing! Submit your details for a callback now https://www.jabezsciences.com/

12/03/2025

At Jabez Biosciences, we’re proving that biotech isn’t a win-or-lose game; it’s about combining strengths. Our oral, DHODH inhibitor JBZ-001 is designed to seamlessly complement existing cancer treatments, boosting impact without adding burden.
For patients, this means access and dignity. For clinicians, it offers flexibility. For investors, it presents a rare pre-IPO opportunity in scalable, synergy-driven oncology.
We’re building the future of cancer care together. Share your thoughts.
Watch: https://youtu.be/RJPwLI41QAI
Don’t wait, be part of the future of healing! Submit your details for a callback now https://www.jabezsciences.com/

11/17/2025

We’re not trying to be the flashiest biotech in the room; we’re the biotech quietly working to improve cancer care. 💙
Meet JBZ-001, our Phase 1 DHODH inhibitor, powered by our 3-S model for smarter therapeutic approaches.
Curious how we’re reshaping the future of cancer therapeutics?
🎥 Watch our story: https://youtu.be/RJPwLI41QAI?si=put-oX2rl7YYcHIh
Whether you’re a patient, caregiver, clinician, or potential partner,
📞 Share your details for a friendly callback: https://www.jabezsciences.com/